BJMO - volume 13, issue 6, october 2019
C. Debeuckelaere MD, L. Triest MD, T. Vandamme MD, B. Van Den Heuvel MD, K. Papadimitriou MD, M. Rasschaert MD, H. Prenen MD, PhD, M. Peeters MD, PhD
For over a decade, oxaliplatin-based adjuvant chemotherapy has been the gold standard for resected early colon cancer. Oxaliplatin is known to cause polyneuropathy, which affects quality of life dramatically. In recent years, there has not been any progress in the development of novel agents to replace oxaliplatin as adjuvant therapy. Consequently, there is a growing interest to investigate whether a shorter course of chemotherapy is sufficient. This article will discuss the history of adjuvant treatment in early-resected colon cancer, the toxicity of oxaliplatin, the results from the IDEA meta-analysis and future prospects.
(BELG J MED ONCOL 2019;13(6):234–239)
Read moreBJMO - volume 12, issue 8, december 2018
B. Van Den Heuvel MD, M. Rasschaert MD, L. Triest MD, C. Debeuckelaere MD, F. Couturier , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD
Although none of the submitted abstracts in the field of gastro-intestinal oncology reached the presidential sessions of ESMO 2018, some practice-changing and promising data were presented especially in the field of immunotherapy. This report summarises the highlights in the field of colorectal, anal and upper digestive tract cancer.
Read moreBJMO - volume 12, issue 4, august 2018
M. Rasschaert MD, L. Triest MD, J. Van den Brande , K. Papadimitriou MD, H. Prenen MD, PhD, M. Peeters MD, PhD
The 2018 annual meeting of the American Society of Oncology (ASCO) was once more hosted in Chicago. Over 40,000 oncologists attended this years’ convention. This report will summarize the highlights from the gastro-intestinal cancer sessions at the meeting.
Read moreBJMO - volume 11, issue 7, november 2017
L. Triest MD, K. Papadimitriou MD, M. Rasschaert MD, J. Van den Brande , M. Peeters MD, PhD
ESMO 2017 featured the presentation of several practice changing data in the field of gastrointestinal (GI) cancer. The first part of this report will summarize the key data presented in the field of gastric cancer, gastroesophageal junction (GEJ), biliary, gallbladder, biliary, pancreatic and hepatocellular cancer. In the second part, the focus is turned to colorectal cancer.
(BELG J ONCOL 2017;11(7):340–348)
Read more
Top
